R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: Implications for prophylaxis and treatment of colon cancer

Cancer Research

Volumn 57, Issue 19, 1997, Pages 4316-4324

  Wechter, William J ^a   Kantoci, Darko ^a   Murray Jr , E David ^a   Quiggle, David D ^a   Leipold, Douglas D ^a   Gibson, Karina M ^a   McCracken, John D ^a  

^a LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLURBIPROFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON CANCER; COLON POLYPOSIS; COLON ULCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; LIPID DIET; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR VOLUME;

ADENOMA; ADENOMATOUS POLYPOSIS COLI; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; BODY WEIGHT; CELL DIVISION; CHEMOPREVENTION; DIETARY FATS; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLURBIPROFEN; GENES, APC; HETEROZYGOTE; INTESTINAL DISEASES; INTESTINAL NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MOLECULAR STRUCTURE; ULCER;

EID: 0030880514     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Wingo, P., Tong, T., and Bolden, S. Cancer statistics. CA Cancer J. Clin., 45: 8-30, 1995.
2. Lipkin, M. Biomarkers of increased susceptibility to gastrointestinal cancer: new application to studies of cancer prevention in human subjects. Cancer Res., 48: 235-245, 1988.
3. Kelloff, G. J., Boone, C. W., Steele, V. E., Crowell, J. A., Lubet, R., and Sigman, C. C. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res., 54: 2015S-2024S, 1994.
4. Bedi, A., Pasricha, P. J., Akhtar, A. J., Barber, J. P., Bedi, G. C., Giardiello, F. M., Zehnbauer, B. A., Hamilton, S. R., and Jones, R. J. Inhibition of apoptosis during development of colorectal cancer. Cancer Res., 55, 1811-1816, 1995.
5. Welberg, J. W. M., de Vries, E. G. E., Hardonk, M. J., Mulder, N. H., Harms, G., Grond, J., Zwart, N., Koudstaal, J., de Ley, L., and Kleibeuker, J. H. Proliferation rate of colonic mucosa in normal subjects and patients with colonie neoplasms: a refined immunohistochemical method. J. Clin. Pathol., 43: 453-456, 1990.
6. Morin, P. J., Vogelstein, B., and Kinzler, K. W. Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. USA, 93: 7950-7954, 1996.
7. Vogelstein, B., Fearon, E., Hamilton, S. R., Kern, S., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A., and Bos, J. Genetic alterations during colorectal-tumor development. N. Engl. J. Med., 319: 525-532, 1988.
8. Groden, J., Thliveris, A., Samowitz, W., Carlson, M., Gelbert, L., Albertsen, H., Joslyn, G., Stevens, J., Spirio, L., Robertson, M., Sargeant, L., Krapcho, K., Wolff, E., Burt, R., Hughes, J. P., Warrington, J., McPherson, J., Wasmuth, J., Le Paslier, D., Abderrahim, H., Cohen, D., Leppert, M., and White, R. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 66, 589-600, 1991.
9. Thun, M. J., Namboodiri, M. M., and Heath, C. W., Jr. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325: 1593-1596, 1991.
10. Suh, O., Mettlin, C., and Petrelli, N. Aspirin use, cancer, and polyps of the large bowel. Cancer (Phila.), 72: 1171-1177, 1993.
11. Katusic, S., Beard, C. M., Kurland, L. T., Weis, J. W., and Bergstralh, E. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am. J. Med., 78: 50-55, 1985.
12. Giovannucci, E., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C., and Speizer, F. E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 333: 609-614, 1995.
13. Labayle, D., Fischer, D., Vielh, P. Droughin, F., Pariente, A., Bories, C., Duhamel, O., Trousset, M., and Attali, P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology, 101: 635-639, 1991.
14. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, G. J. A. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328: 1313-1316, 1993.
15. Rigau, J., Pique, J., Rubio, E., Planas, R., Tarrech, J. M., and Bordas, J. M. Effects of long-term sulindac therapy on colonic polyposis. Ann. Intern. Med., 115: 952-955, 1991.
16. Jacoby, R. F., Marshall, D. J., Newton, M. A., Navakovic, I., Tutsch, K., Cole, C. E., Lubet, R. A., Kelloff, G. J., Verma, A., Moser, A. R., and Dove, W. F. Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res., 56: 710-714, 1996.
17. Reddy, B. S., Maruyama, H., and Kelloff, G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res., 47: 5340-346, 1987.
18. Marnett, L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res., 52: 5575-5589, 1992.
19. Sato, M., Narisawa, T., Sano, M., Takahasi, T., and Goto, A. Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin. J. Cancer Res. Clin. Oncol., 106: 21-26, 1983.
20. Reddy, B. S., Rao, C. V., Rivenson, A., and Kelloff, G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis (Lond.), 14: 1493-1497, 1993.
21. Narisawa, T., Kusaka, H., Yamazaki, Y., Takahashi, M., Koyama, H., Koyama, K., Fukaura, Y., and Wakizaka, A. Relationship between blood plasma prostaglandin E2 and liver and lung metastases in colorectal cancer. Dis. Colon Rectum. 33: 840-845, 1990.
22. Carter, C. A., Ip, M. M., and Ip, C. A comparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acid. Carcinogenesis (Lond.), 10: 1369-1374, 1989.
23. Gustafson-Svärd, C., Lilja, I., Hallböök, O., and Sjödahl, R. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonie tumours in rats. Gut, 38: 79-84, 1996.
24. Grossman, C. J., Wiseman, J., Lucas, F. S., Trevethick, M. A., and Birch, P. J. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and COX 2 inhibitors. Inflamm. Res., 44: 253-257, 1995.
25. Hanif, R., Pittas, A., Feng, Y., Koutsos, M., Shift, S. J., Staiano-Coico, L., and Rigas, B. NSAIDs inhibit the growth of colon cancer cell lines by a prostaglandin independent pathway. Gastroenterology, 108: A478, 1995.
26. Schnitzler, M., Dwight, T., and Robinson, B. G. Sulindac increases the expression of APC mRNA in malignant colonie epithelial cells: an in vitro study. Gut, 38: 707-713, 1996.
27. Goldberg, Y., Pittas, A., Reed, J. C., Rigas, B., and Shiff, S. J. Sulindac and sulindac sulfide alter the levels of Bcl-2 and Bax proteins in HT-29 colon cancer cells. Gastroenterology, 108: A475, 1995.
28. Singh, J., Kelloff, G., and Reddy, B. S. Intermediate biomarkers of colon cancer: modulation of expression of ras oncogene by chemopreventive agents during azoxymethane induced colon carcinogenesis. Carcinogenesis (Lond.), 14: 699-704, 1993.
29. McCracken, J. D., Wechter, W. J., Liu, Y., Chase, R. L., Kantoci, D., Murray, E. D., Jr., Quiggle, D. D., and Mineyama, Y. Antiproliferative effects of the enantiomers of flurbiprofen. J. Clin. Pharmacol., 36: 540-545, 1996.
30. Carabaza, A., Cabré, F., Rotllan, E., Gómez, M., Gutiérrez, M., García, M. L., and Mauleón, D. Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs. J. Clin. Pharmacol., 36: 505-512, 1996.
31. McCracken, J. D., Jacoby, R. F., Kantoci, D., Murray, E. D., Jr., and Wechter, W. J. The effect of R-flurbiprofen on inhibition of polyp formation in the Min mouse model. Gastroenterology, 110: A555, 1996.
32. Moser, A. R., Pilot, H. C., and Dove, W. F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science (Washington DC), 247: 322-324, 1990.
33. Moser, A. R., Dove, W. F., Roth, K. A., and Gordon, J. I. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J. Cell Biol., 116: 1517-1526, 1992.
34. Su, L-K., Kinzler, K. W., Vogelstein, B., Preisinger, A. C., Moser, A. R., Luongo, C., Gould, K. A., and Dove, W. F. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science (Washington DC), 256: 668-670, 1992.
35. Daniel, W. W. Applied Nonparametric Statistics, Ed. 2, pp. 240-242. Boston: PWS-KENT Publishing Co., 1990.
36. Gibaldi, M., and Perrier, D. Absorption kinetics and bioavailability. In: J. Swarbrick (ed.), Pharmacokinetics. Drugs and The Pharmaceutical Sciences, Ed. 2, Vol. 15, pp. 145-198. New York: Marcel Dekker, Inc., 1982.
37. Wechter, W. J., McCracken, J. D., Kantoci, D., Murray, E. D., Jr., Quiggle, D., Leipold, D., Gibson, K., Mineyama, Y., and Liu, Y. On the mechanism of the enhancement of ulcerogenicity of S-aryl propionic acids by their R-enantiomers in the rat. Dig. Dis. Sci., in press, 1997.
38. Menzel-Soglowek, S., Geisslinger, G., Beck, W. S., and Brune, K. Variability of inversion of (R)-flurbiprofen in different species. J. Pharm. Sci., 81: 888-891, 1992.